Lexington, Kentucky, United States
I serve as the Director of the Drug & Disease Discovery (D3) Research Center and the principal investigator of the Hinds Lab, where our research focuses on advancing the scientific foundations of precision medicine through rigorous molecular discovery, drug development, and translational innovation. Our laboratory operates at the leading edge of kinase biology and nuclear receptor pharmacology. We are among a select number of research groups worldwide with deep expertise in the PamGene PamStation platform, which enables the simultaneous profiling of hundreds of kinase activities from a single biological sample. This capability allows us to characterize drug response across more than 500 signaling pathways at the individual patient level — providing mechanistic insight critical to understanding therapeutic efficacy, off-target effects, and interpatient variability. Complementing this, our laboratory maintains exclusive access to a PamGene PamChip for Nuclear Hormone Receptors, which quantifies binding interactions between 155 coregulators and their respective receptors. This technology offers unparalleled resolution into how pharmaceutical compounds modulate nuclear receptor activity and downstream gene transcription. Our patent-pending methodologies built upon these platforms represent substantive contributions to the emerging field of personalized medicine. The Hinds Lab has established a distinguished record of discovery. Notable achievements include the foundational discovery that bilirubin acts as a hormone via receptor-mediated responses mediated by the PPARα nuclear receptor. These findings led to the development of novel compounds for the treatment of obesity, diabetes, MASLD, and cardiovascular disease. The identification of the murine glucocorticoid receptor β gene, the development of the world's first and only human GRβ antagonist, and the engineering of the advanced PamGene technology for personalized medicine and clinical trials in a PamChip used for drug discovery, mechanisms of action, and targetable outcomes in patients. Our most recent work has identified novel hormones associated with obesity-related comorbidities, with patent filings and publications currently in preparation. I welcome connections with academic researchers, clinicians, and industry collaborators committed to advancing science with meaningful global impact; the Book Appointment button is for this purpose. My team and I are always open to discussing potential partnerships or exploring how our platform capabilities may support your research objectives.
Founding Director of the Drug & Disease Discovery D3 Research Center
Publisher: Portland Press. Print ISSN 0143-5221, Online ISSN 1470-8736 *Published by Portland Press on behalf of the Biochemical Society.
Publisher: Oxford University Press. Online ISSN 2052-0034
Publisher: Elsevier. Print ISSN: 0026-0495, Online ISSN: 1532-8600